Ensign Peak Advisors Inc Purchases 29,697 Shares of AbbVie Inc. (NYSE:ABBV)

Ensign Peak Advisors Inc lifted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,059,389 shares of the company's stock after buying an additional 29,697 shares during the quarter. AbbVie comprises approximately 0.7% of Ensign Peak Advisors Inc's holdings, making the stock its 25th largest position. Ensign Peak Advisors Inc owned 0.12% of AbbVie worth $365,953,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ABBV. Fiduciary Advisors Inc. acquired a new stake in AbbVie during the fourth quarter worth about $29,000. EnRich Financial Partners LLC lifted its position in shares of AbbVie by 196.4% in the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after acquiring an additional 110 shares during the period. Promus Capital LLC bought a new stake in shares of AbbVie during the fourth quarter valued at approximately $30,000. Bradley & Co. Private Wealth Management LLC acquired a new position in shares of AbbVie in the fourth quarter valued at $31,000. Finally, Prudent Man Investment Management Inc. bought a new position in AbbVie in the fourth quarter worth $32,000. 70.23% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Perry C. Siatis sold 5,778 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the completion of the transaction, the executive vice president now owns 22,381 shares in the company, valued at approximately $4,429,199.90. This represents a 20.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the transaction, the executive vice president now directly owns 53,234 shares of the company's stock, valued at $11,183,398.72. This represents a 52.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 113,471 shares of company stock valued at $23,426,451 in the last ninety days. 0.08% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ABBV has been the topic of several recent research reports. Bank of America lifted their target price on shares of AbbVie from $200.00 to $223.00 and gave the company a "neutral" rating in a research report on Tuesday, March 4th. Wells Fargo & Company upped their price objective on AbbVie from $210.00 to $240.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Truist Financial raised their target price on AbbVie from $211.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. BMO Capital Markets upped their price target on AbbVie from $208.00 to $215.00 and gave the company an "outperform" rating in a research report on Monday, February 3rd. Finally, Erste Group Bank raised AbbVie to a "strong-buy" rating in a report on Monday, March 17th. Seven research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, AbbVie has a consensus rating of "Moderate Buy" and a consensus price target of $211.41.

AbbVie Stock Down 0.7 %

AbbVie stock traded down $1.28 during trading on Friday, hitting $184.30. 7,806,084 shares of the company were exchanged, compared to its average volume of 6,133,352. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The business's 50 day moving average is $194.23 and its 200 day moving average is $187.23. AbbVie Inc. has a 52 week low of $153.58 and a 52 week high of $218.66. The company has a market capitalization of $326.02 billion, a P/E ratio of 76.79, a PEG ratio of 1.62 and a beta of 0.56.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, April 25th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.40 by $0.06. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The company had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. During the same quarter in the prior year, the company posted $2.31 earnings per share. The firm's revenue for the quarter was up 8.4% on a year-over-year basis. Analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be paid a $1.64 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.56%. AbbVie's dividend payout ratio (DPR) is presently 279.15%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.